AccurEdit Therapeutics' ART001 Becomes First Gene Editing Therapy in China to Achieve FDA RMAT Designation AccurEdit Therapeutics announced ART001, China's first gene editing therapy, received FDA RMAT designation, expediting its clinical development.

AccurEdit Therapeutics' ART001 Becomes First Gene Editing Therapy in China to Achieve FDA RMAT Designation #China #Suzhou #AccurEdit #ART001 #FDA_RMAT

AccurEdit Therapeutics to Present Groundbreaking Research at ASGCT 2025 AccurEdit Therapeutics will showcase its innovative abstracts at the 2025 ASGCT, highlighting advances in gene editing technology and its pivotal ART001 therapy.

AccurEdit Therapeutics to Present Groundbreaking Research at ASGCT 2025 #United_States #New_Orleans #Gene_Editing #AccurEdit #ART001